Product Citations: 42

1 image found

p300 inhibition delays premature cellular senescence.

In Npj Aging on 10 July 2025 by Di Fede, E., Taci, E., et al.

Cellular senescence represents a permanent state of cell cycle arrest, also observed in neurodegenerative disorders. As p300 has been identified as an epigenetic driver of replicative senescence, we aimed to investigate whether in vitro p300 inhibition could rescue the stress-induced premature senescence (SIPS) phenotype. We exploited 2D and 3D (brain organoids) in vitro models of SIPS using two different stressor agents. In addition, we combined the treatment with a p300 inhibitor and validated p300 role in SIPS by analyzing different senescence markers and the transcriptome in our models. Interestingly, p300 inhibition can counteract the DNA damage and SIPS phenotype, detecting a dysregulation of gene expression and protein translation associated with the senescence program. These findings highlight both the molecular mechanisms underlying senescence and p300 as a possible pharmacological target. Thus, targeting p300 and, by extension, senescent cells could represent a promising therapeutic strategy for age-related diseases such as neurodegenerative disorders.
© 2025. The Author(s).

The anticancer potential of Origanum onites L. in gastric cancer through epigenetic alterations.

In BMC Complementary Medicine and Therapies on 2 July 2025 by Sogutlu, F., Pekerbas, M., et al.

Epigenetic alterations are crucial in gastric cancer (GC) development and progression. As these modifications are reversible, targeting them may offer preventive and therapeutic benefits. Origanum onites L. essential oil (OOEO) has demonstrated anticancer properties in various cancers, but its epigenetic effects in GC remain unexplored.
OOEO was extracted by water distillation, and its effects on gastric adenocarcinoma (AGS) and normal gastric epithelial (GES-1) cells were evaluated. Cytotoxicity was assessed via WST-8 assay, apoptosis by Annexin V staining, DNA damage by γ-H2AX test, and epigenetic modifications by methylation-specific PCR and histone modification analysis.
Compared to GES-1 cells, OOEO exhibited cytotoxic activity even at lower concentrations in AGS cells. OOEO treatment induced apoptosis and DNA double-strand breaks and arrested cell cycle at S and G2/M phases compared to the untreated group. OOEO also caused a decrease in promoter methylation of LOX, TIMP3, CDH1 and RARB genes and was found to globally alter 16 histone modifications in AGS cells and 19 histone modifications in GES-1 cells. OOEO contributed to the reorganization of H3K9ac modification in the promoters of CDKN1A, MYC, RUNX3, RASSF1 and CDH1 genes and H3K27me3 modification in the promoters of CDKN1A and MYC genes.
OOEO exhibits epigenetic regulatory properties that may contribute to GC prevention and treatment. Its potential in neoadjuvant or combinatory therapies warrants further investigation.
© 2025. The Author(s).

  • Cancer Research
  • Genetics

Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss.

In Journal of Cell Science on 1 August 2024 by Bouley, S. J., Grassetti, A. V., et al.

Neurofibromatosis type 1, a genetic disorder caused by pathogenic germline variations in NF1, predisposes individuals to the development of tumors, including cutaneous and plexiform neurofibromas (CNs and PNs), optic gliomas, astrocytomas, juvenile myelomonocytic leukemia, high-grade gliomas and malignant peripheral nerve sheath tumors (MPNSTs), which are chemotherapy- and radiation-resistant sarcomas with poor survival. Loss of NF1 also occurs in sporadic tumors, such as glioblastoma (GBM), melanoma, breast, ovarian and lung cancers. We performed a high-throughput screen for compounds that were synthetic lethal with NF1 loss, which identified several leads, including the small molecule Y102. Treatment of cells with Y102 perturbed autophagy, mitophagy and lysosome positioning in NF1-deficient cells. A dual proteomics approach identified BLOC-one-related complex (BORC), which is required for lysosome positioning and trafficking, as a potential target of Y102. Knockdown of a BORC subunit using siRNA recapitulated the phenotypes observed with Y102 treatment. Our findings demonstrate that BORC might be a promising therapeutic target for NF1-deficient tumors.
© 2024. Published by The Company of Biologists Ltd.

  • ICC-IF
  • Cell Biology
  • Genetics

Cooperativity between Cas9 and hyperactive AID establishes broad and diversifying mutational footprints in base editors.

In Nucleic Acids Research on 28 February 2024 by Berrios, K. N., Barka, A., et al.

The partnership of DNA deaminase enzymes with CRISPR-Cas nucleases is now a well-established method to enable targeted genomic base editing. However, an understanding of how Cas9 and DNA deaminases collaborate to shape base editor (BE) outcomes has been lacking. Here, we support a novel mechanistic model of base editing by deriving a range of hyperactive activation-induced deaminase (AID) base editors (hBEs) and exploiting their characteristic diversifying activity. Our model involves multiple layers of previously underappreciated cooperativity in BE steps including: (i) Cas9 binding can potentially expose both DNA strands for 'capture' by the deaminase, a feature that is enhanced by guide RNA mismatches; (ii) after strand capture, the intrinsic activity of the DNA deaminase can tune window size and base editing efficiency; (iii) Cas9 defines the boundaries of editing on each strand, with deamination blocked by Cas9 binding to either the PAM or the protospacer and (iv) non-canonical edits on the guide RNA bound strand can be further elicited by changing which strand is nicked by Cas9. Leveraging insights from our mechanistic model, we create novel hBEs that can remarkably generate simultaneous C > T and G > A transitions over >65 bp with significant potential for targeted gene diversification.
© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.

  • Biochemistry and Molecular biology

Quinoline-based thiazolyl-hydrazones target cancer cells through autophagy inhibition.

In Archiv Der Pharmazie on 1 February 2024 by Ćurčić, V., Olszewski, M., et al.

Heterocyclic pharmacophores such as thiazole and quinoline rings have a significant role in medicinal chemistry. They are considered privileged structures since they constitute several Food and Drug Administration (FDA)-approved drugs for cancer treatment. Herein, we report the synthesis, in silico evaluation of the ADMET profiles, and in vitro investigation of the anticancer activity of a series of novel thiazolyl-hydrazones based on the 8-quinoline (1a-c), 2-quinoline (2a-c), and 8-hydroxy-2-quinolyl moiety (3a-c). The panel of several human cancer cell lines and the nontumorigenic human embryonic kidney cell line HEK-293 were used to evaluate the compound-mediated in vitro anticancer activities, leading to [2-(2-(quinolyl-8-ol-2-ylmethylene)hydrazinyl)]-4-(4-methoxyphenyl)-1,3-thiazole (3c) as the most promising compound. The study revealed that 3c blocks the cell-cycle progression of a human colon cancer cell line (HCT-116) in the S phase and induces DNA double-strand breaks. Also, our findings demonstrate that 3c accumulates in lysosomes, ultimately leading to the cell death of the hepatocellular carcinoma cell line (Hep-G2) and HCT-116 cells, by the mechanism of autophagy inhibition.
© 2023 Deutsche Pharmazeutische Gesellschaft.

  • Cancer Research
  • Cell Biology
View this product on CiteAb